Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Return on Equity (2021 - 2024)

Immuneering has reported Return on Equity over the past 4 years, most recently at 0.95% for Q3 2024.

  • Quarterly results put Return on Equity at 0.95% for Q3 2024, down 47.0% from a year ago — trailing twelve months through Sep 2024 was 0.95% (down 47.0% YoY), and the annual figure for FY2023 was 0.55%, down 17.0%.
  • Return on Equity for Q3 2024 was 0.95% at Immuneering, down from 0.79% in the prior quarter.
  • Over the last five years, Return on Equity for IMRX hit a ceiling of 0.79% in Q1 2021 and a floor of 0.95% in Q3 2024.
  • Median Return on Equity over the past 4 years was 0.46% (2021), compared with a mean of 0.33%.
  • Peak annual rise in Return on Equity hit 9bps in 2022, while the deepest fall reached -108bps in 2022.
  • Immuneering's Return on Equity stood at 0.21% in 2021, then plummeted by -104bps to 0.44% in 2022, then fell by -29bps to 0.56% in 2023, then crashed by -69bps to 0.95% in 2024.
  • The last three reported values for Return on Equity were 0.95% (Q3 2024), 0.79% (Q2 2024), and 0.66% (Q1 2024) per Business Quant data.